Background/Aims: Troglitazone is one of thiazolidinedione derivatives as a high affinity ligand for peroxisome proliferator-activated receptor-gamma (PPAR-γ). The in vivo studies demonstrated that troglitazone ameliorated microalbuminuria. There have been few reports about direct effect of thiazolidinedione derivatives on mesangial cell function. We determined the effect of troglitazone on isolated rat mesangial cell proliferation. Methods: We determined PPAR-γ mRNA expression in isolated rat mesangial cells. Chronic effects of 10–6 to 10–4 mol/l troglitazone on mesangial cell proliferation and mitogen-activated protein (MAP) kinase activity were also determined. The effects of troglitazone on apoptosis were investigated in rat mesangial cells. Results: Rat PPAR-γ mRNA was detected in isolated rat mesangial cells. Living cell number, assessed by colorimetric [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (MTT) assay, was significantly decreased with 10–4 mol/l troglitazone. The addition of 10–6 to 10–4 mol/l troglitazone dose-dependently inhibited 5-bromo-2′-deoxyuridine (BrdU) uptake into isolated rat mesangial cells. The addition of 10–4 and 10–5 mol/l troglitazone significantly reduced MAP kinase activity. Troglitazone at the concentrations of 10–6 to 10–4 mol/l dose-dependently increased DNA fragmentation rates, indicating that troglitazone may cause apoptosis in rat mesangial cells. Bax and Bcl-xL proteins were not changed, although Bcl-2 proteins increased with troglitazone. Conclusions: The present data demonstrated that troglitazone inhibits cell proliferation, and induces apoptosis in rat mesangial cells, raising a possibility that it directly affects renal function.

1.
Striker LJ, Doi T, Elliot S, Striker GE: The contribution of glomerular mesangial cells to progressive glomerulosclerosis. Semin Nephrol 1989;9:318–328.
2.
Steffes MW, Osterby R, Chavers B, Mauer SM: Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 1989;38:1077–1081.
3.
Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN: High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-beta. Kidney Int 1992;42:647–656.
4.
Kikkawa R, Umemura K, Haneda M, Kajiwara N, Maeda S, Nishimura C, Shigeta Y: Identification and characterization of aldose reductase in cultured rat mesangial cells. Diabetes 1992;41:1165–1171.
5.
Kikkawa R, Umemura K, Haneda M, Arimura T, Ebata K, Shigeta Y: Evidence for existence of polyol pathway in cultured rat mesangial cells. Diabetes 1987;36:240–243.
6.
Kikkawa R, Haneda M, Uzu T, Koya D, Sugimoto T, Shigeta Y: Translocation of protein kinase C alpha and zeta in rat glomerular mesangial cells cultured under high glucose conditions. Diabetologia 1994;37:838–841.
7.
Haneda M, Arai S, Togawa M, Sugimoto T, Isono M, Kikkawa R: Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 1997;46:847–853.
8.
Ishii H, Koya D, King GL: Protein kinase C activation and its role in the development of vascular complication in diabetes mellitus. J Mol Med 1998;76:21–31.
9.
Koya D, King GL: Protein kinase C activation and the development of diabetic complication. Diabetes 1998;47:859–866.
10.
Pugliese G, Pricci F, Romeo G, Pugliese F, Mene P, Gianni S, Cresci B, Galli G, Rotella CM, Vlassara H, Di Mario U: Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 1997;46:1881–1887.
11.
Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045: Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988;37:1549–1558.
12.
Fujiwara T, Wada M, Fukuda K, Fukami M, Yoshioka S, Yoshioka T, Horikoshi H: Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 1991;40:1213–1218.
13.
Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188–1193.
14.
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995;270:12953–12956.
15.
Fujii M, Takemura R, Yamaguchi M, Hasegawa G, Shigeta H, Nakano K, Kondo M: Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. Metabolism 1997;46:981–983.
16.
Nicholas SB, Kawano Y, Wakino S, Collins AR, Hsueh WA: Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells. Hyertension 2001;37:722–727.
17.
Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, Kajimoto Y, Yamasaki Y, Hori M: Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998;21:2135–2139.
18.
Asano T, Wakisaka M, Yoshinari M, Iino K, Sonoki K, Iwase M, Fujishima M: Peroxisome proliferator-activated receptor gamma 1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. Biochm Biophys Acta 2000;1497:148–154.
19.
Rovin BH, Wilmer WA, Lu L, Doseff AI, Dixon C, Kotur M, Hilbelink T: 15-deoxy-delta 12,14-prostaglandin J2 regulates mesangial cell proliferation and death. Kidney Int 2002;61:1293–1302.
20.
Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytoxicity assays. J Immunol Methods 1983;65:55–63.
21.
Porstmann T, Ternynck T, Avrameas S: Quantification of 5-bromo-2-deoxyuridine incorporation into DNA: An enzyme immunoassay for the assessment of the lymphoid cell proliferative response. J Immunol Methods 1985;82:169–179.
22.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–275.
23.
Ezawa K, Minato K, Dobashi K: Induction of apoptosis by ubenimex (Bestatin®) in human non-small-cell lung cancer cell lines. Biomed Pharmacother 1996;50:283–289.
24.
Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:906–919.
25.
Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB: Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597–608.
26.
Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334–336.
27.
Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 1996;137:354–366.
28.
Buckingham RE, Al-Barazanji KA, Toseland CD, Slaighter M, Connor SC, West A, Bond B, Turner NC, Clapham JC: Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker Fatty rats. Diabetes 1998;47:1326–1334.
29.
Festa A, D’Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM: Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 2000;58:1703–1710.
30.
Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679–684.
31.
Shibata H, Nii S, Kobayashi M: Phase I study of a new hypoglycemic agent CS-045 in healthy volunteers: Safety and pharmacokinetics in single administration. Rinsho Iyaku 1993;9:1503–1518.
32.
Heilig CW, Liu Y, England RL, Freytag SO, Gilbert JD, Heilig KO, Zhu M, Concepcion LA, Brosius FC 3rd: D-Glucose stimulates mesangial cell GLUT1 expression and basal and IGF-I-sensitive glucose uptake in rat mesangial cells: Implications for diabetic nephropathy. Diabetes 1997;46:1030–1039.
33.
Asano T, Wakisaka M, Yoshinari M, Nakamura S, Doi Y, Fujishima M: Troglitazone enhances glycolysis and improves intracellular glucose metabolism in rat mesangial cells. Metabolism 2000;49:308–313.
34.
Matsuo H, Yamasaki H, Matsumoto K, Uotani S, Yamaguchi Y, Akazawa S, Yamashita S, Nagataki S: Adenosine 3′,5′-cyclic monophosphate mimics the inhibitory effect of high glucose on MAP kinase phosphorylation in rat mesangial cells. Biochem Biophys Res Commun 1996;226:746–754.
35.
Sugimoto T, Kikkawa R, Haneda M, Shigeta Y: Atrial natriuretic peptide inhibits endothelin-1-induced activation of mitogen-activated protein kinase in cultured rat mesangial cells. Biochem Biophys Res Commun 1993;195:72–78.
36.
Haneda M, Kikkawa R, Sugimoto T, Koya D, Araki S, Togawa M, Shigeta Y: Abnormalities in protein kinase C and MAP kinase cascade in mesangial cells cultured under high glucose conditions. J Diab Complications 1995;9:246–248.
37.
Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP: Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998;95:8806–8811.
38.
Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y: Activation of PPAR gamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999;455:135–139.
39.
Hirase N, Yanase T, Mu Y, Muta K, Uemura T, Takayanagi R, Nawata H: Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60. Oncology 1999;57(suppl 2):17–26.
40.
Ohtani K, Shimizu H, Sato N, Mori M: Troglitazone (CS-045) inhibits beta-cell proliferation rate following stimulation of insulin secretion in HIT-T 15 cells. Endocrinology 1998;139:172–178.
41.
Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998;101:1354–1361.
42.
Conner EA, Teramoto T, Wirth PJ, Kiss A, Garfield S, Thorgeirsson SS: HGF-mediated apoptosis via p53/bax-independent pathway activating JNK1. Carcinogenesis 1999;20:583–590.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.